Case Background:
This is a federal securities fraud class action lawsuit on behalf of investors who purchased or otherwise acquired Alnylam Pharmaceuticals, Inc. (“Alnylam”) (NASDAQ: ALNY) securities between September 20, 2017 and September 12, 2018, inclusive (the “Class Period”).
Alnylam is a biopharmaceutical company focused on the development and commercialization of therapies for genetic diseases.
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and (2) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On March 23, 2020, the Court granted Defendants' Motion to Dismiss. On June 1, 2020, Lead Plaintiffs requested permission from the Court to amend the complaint, and on March 12, 2021, the Court denied Plaintiffs’ request. This action has concluded.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.